chromogranin a Search Results


anti chromogranin a  (Novus Biologicals)
94
Novus Biologicals anti chromogranin a
Anti Chromogranin A, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pm28572005-42-25-29?v=Novus+Biologicals
Average 94 stars, based on 1 article reviews
anti chromogranin a - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
1 ap  (Proteintech)
95
Proteintech 1 ap
1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pmc11178405__2005845__f1-0-4-10?v=Proteintech
Average 95 stars, based on 1 article reviews
1 ap - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
chromogranin a  (Novus Biologicals)
94
Novus Biologicals chromogranin a
Chromogranin A, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pmc11442308-3-3-0?v=Novus+Biologicals
Average 94 stars, based on 1 article reviews
chromogranin a - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
mouse anti chromogranin a cga  (Novus Biologicals)
90
Novus Biologicals mouse anti chromogranin a cga
Mouse Anti Chromogranin A Cga, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pmc05824736-450-70-76?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
mouse anti chromogranin a cga - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
c8198 rrid ab 259091 chromogranin a chga novus biologicals  (Novus Biologicals)
94
Novus Biologicals c8198 rrid ab 259091 chromogranin a chga novus biologicals
C8198 Rrid Ab 259091 Chromogranin A Chga Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pm38788720-1037-56-62?v=Novus+Biologicals
Average 94 stars, based on 1 article reviews
c8198 rrid ab 259091 chromogranin a chga novus biologicals - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
human cga elisa kit  (Novus Biologicals)
90
Novus Biologicals human cga elisa kit
Figure 6. Elevated <t>CGA</t> and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) <t>ELISA</t> of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).
Human Cga Elisa Kit, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/10__1172_slash_jci154074-359-1-5?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
human cga elisa kit - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
nbp2-29428  (novus biologicals)
93
novus biologicals nbp2-29428
Figure 6. Elevated <t>CGA</t> and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) <t>ELISA</t> of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).
Nbp2 29428, supplied by novus biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pmc11930733-4-0-2?v=novus+biologicals
Average 93 stars, based on 1 article reviews
nbp2-29428 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
chga  (OriGene)
93
OriGene chga
Figure 6. Elevated <t>CGA</t> and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) <t>ELISA</t> of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).
Chga, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pmc12090326-64-0-2?v=OriGene
Average 93 stars, based on 1 article reviews
chga - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
chromogranin a  (OriGene)
90
OriGene chromogranin a
Figure 6. Elevated <t>CGA</t> and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) <t>ELISA</t> of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).
Chromogranin A, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pm27347150-59-79-91?v=OriGene
Average 90 stars, based on 1 article reviews
chromogranin a - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
ccugaugaucgaagaguauuu gadcdc  (OriGene)
90
OriGene ccugaugaucgaagaguauuu gadcdc
Figure 6. Elevated <t>CGA</t> and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) <t>ELISA</t> of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).
Ccugaugaucgaagaguauuu Gadcdc, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/pm26230090-200-37-39?v=OriGene
Average 90 stars, based on 1 article reviews
ccugaugaucgaagaguauuu gadcdc - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
overexpression lysates  (OriGene)
90
OriGene overexpression lysates
Figure 6. Elevated <t>CGA</t> and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) <t>ELISA</t> of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).
Overexpression Lysates, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chromogranin+a/mcwade_melanie_ann__2016__development_of_an_intraoperative_tool_to_detect_parathyroid_gland_autofluorescence-3410-1-6?v=OriGene
Average 90 stars, based on 1 article reviews
overexpression lysates - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Figure 6. Elevated CGA and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) ELISA of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).

Journal: Journal of Clinical Investigation

Article Title: A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer

doi: 10.1172/jci154074

Figure Lengend Snippet: Figure 6. Elevated CGA and GATA2 expression levels in GC patients after chemotherapy. (A and B) IHC staining of CGA, p-EGFR, and GATA2 in 6 repre- sentative nonresponsive human GC specimens (n = 31) obtained before and after chemotherapy (A). Scale bar: 50 μm. IHC scores of p-EGFR and GATA2 are shown (B). The CGA images are the same as shown in Figure 1D. (C) Association between CGA and p-EGFR or GATA2 levels in nonresponsive GC specimens (n = 31) obtained after chemotherapy. (D) ELISA of CGA levels in plasma samples from healthy donors (normal, n = 57), newly diagnosed GC patients (non-chemo, n = 42), and neoadjuvant (n = 41) or palliative (n = 56) chemotherapy–treated GC patients. (E) Left: ELISA of plasma CGA from GC patients who received neoadjuvant chemotherapy with a partial response (PR, n = 9) or stable disease (SD, n = 31) status. Right: ELISA of plasma CGA from post- and preoperative samples of GC patients (n = 15) who received neoadjuvant chemotherapy. (F) Left: ELISA of plasma CGA from GC patients (n = 46) before and after palliative chemotherapy. Right: ELISA of plasma CGA from GC patients who received palliative chemotherapy and had progressive disease (PD, n = 30) or SD (n = 26) status. (G) Log-rank test for overall survival of GC patients (n = 64) with different CGA levels after neoadjuvant or palliative chemo- therapy. Data are presented as mean ± SEM. P value was calculated by Wilcoxon’s matched-pairs signed-rank test (B), by χ2 test (C), by 1-way ANOVA with Bonferroni’s post hoc test (D), or by Student’s t test (E and F).

Article Snippet: A human CGA ELISA Kit (Novus) was used to quantify human plasma CGA levels.

Techniques: Expressing, Immunohistochemistry, Enzyme-linked Immunosorbent Assay, Clinical Proteomics